PIK3CA mutations in breast cancer with low HER2 / neu expression

PIK3CA mutations in breast cancer with low HER2 / neu expression

Introduction. Disturbances in the PI3K-dependent (PI3K – phosphoinositide 3‑kinase) cascade are characteristic of all types of breast cancer. In particular, 30–40 % of patients with advanced / metastatic hormone-positive HER2‑negative (HER2 – human epidermal growth factor receptor 2) breast cancer c...

Full description

Bibliographic Details
Main Authors:	I. A. Pavlenko, P. E. Povilaitite, V. Yu. Kaciyaev, N. S. Makarevich, A. V. Petrov
Format:	Article
Language:	Russian
Published:	ABV-press 2022-12-01
Series:	Успехи молекулярной онкологии
Subjects:	breast cancer human epidermal growth factor receptor 2 pik3ca mutations
Online Access:	https://umo.abvpress.ru/jour/article/view/480

Similar Items

Results of multicenter testing of PIK3CA somatic mutations in hormone-receptor positive HER2-negative advanced breast cancer
by: Snježana Ramić, et al.
Published: (2023-01-01)

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
by: Katherine E. Hutchinson, et al.
Published: (2023-04-01)

Predictive and prognostic features of early and locally advanced <i>PIK3CA</i>-mutated luminal HER2-negative breast cancer
by: A. I. Stukan, et al.
Published: (2024-01-01)

Association of PIK3CA somatic mutations with clinicopathological parameters in breast cancer
by: Gizem Teoman, et al.
Published: (2024-12-01)

Mutations of the PIK3CA gene in patients with breast cancer in the Krasnoyarsk region
by: A. V. Zyuzyukina, et al.
Published: (2024-07-01)

PIK3CA mutations in endocrine-resistant breast cancer
by: Caroline Schagerholm, et al.
Published: (2024-05-01)

Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project
by: Ana Peixoto, et al.
Published: (2023-02-01)

Target therapy of luminal HER2-negative advanced breast cancer with PIK3CA mutation: combination of alpelisib plus fulvestrant in real clinical practice
by: D. A. Filonenko, et al.
Published: (2021-12-01)

Corrigendum: Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project
by: Ana Peixoto, et al.
Published: (2024-04-01)

Correlation between PIK3CA mutation and clinicopathological features and prognosis of breast cancer
by: Yiheliman·MAIMAITI, CAO Yanzhen, WANG Cuicui, YUE Na, LIANG Liping
Published: (2024-03-01)

The role of ultrasonographic findings for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer
by: Li Shuo, et al.
Published: (2023-11-01)

PIK3CA gene mutation status associated with poor prognosis of breast cancer: a retrospective cohort study
by: Min Yan, et al.
Published: (2025-02-01)

Prevalence and prognosis of PIK3CA mutations in Bulgarian patients with metastatic breast cancer receiving endocrine therapy in first‐line setting
by: R. Gencheva, et al.
Published: (2024-02-01)

CLOVES syndrome caused by mosaic mutation in the PIK3CA gene identified in fibroblasts
by: Magdalena Kłaniewska, et al.
Published: (2021-07-01)

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer
by: Eduardo Terán, et al.
Published: (2024-09-01)

Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of TCGA‑BRCA data
by: Haizhu Chen, et al.
Published: (2023-11-01)

Delineation of the phenotypes and genotypes of facial infiltrating lipomatosis associated with PIK3CA mutations
by: Hongrui Chen, et al.
Published: (2023-07-01)

Case Report: Kaposiform hemangioendothelioma with PIK3CA mutation successfully treated with sirolimus
by: Zuopeng Wang, et al.
Published: (2023-05-01)

PIK3CA, KI67, Estrogen (ER) and Progesterone Receptors (PR) Expression Pattern of in HER2 Positive Breast Cancers
by: Samuel I. Ogenyi, et al.
Published: (2022-02-01)

Identification of activating somatic mutations in the <i>PIK3CA</i> gene in breast tumors and determination of their minimal set for clinical diagnostic testing
by: Ulyana A. Boyarskih, et al.
Published: (2024-09-01)

Network Analysis Reveals A Signaling Regulatory Loop in the PIK3CA-mutated Breast Cancer Predicting Survival Outcome
by: Shauna R. McGee, et al.
Published: (2017-04-01)

Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2‐negative metastatic breast cancer
by: Christin Gasch, et al.
Published: (2016-10-01)

Profiling PIK3CA variants in disorders of somatic mosaicism
by: Bahareh A. Mojarad, et al.
Published: (2023-01-01)

Managing facial infiltrating lipomatosis associated with PIK3CA mutation: From surgery to targeted therapy
by: Hongrui Chen, et al.
Published: (2023-03-01)

The role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategies
by: Haitao Wang, et al.
Published: (2024-10-01)

Case Report: Sustained Complete Response to PI3K Inhibition in a Patient with Metastatic Breast Cancer Harboring PIK3CA, NF1, and CDH1 Mutations
by: Elias A. Chandran, et al.
Published: (2020-08-01)

Uncovering somatic mosaic variants of PIK3CA-related overgrowth disorders – three cases with different clinical presentations
by: M. Tooming, et al.
Published: (2025-01-01)

Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trialResearch in context
by: Antonio Llombart-Cussac, et al.
Published: (2024-05-01)

Genomic dissection and mutation-specific target discovery for breast cancer PIK3CA hotspot mutations
by: Adam X. Miranda, et al.
Published: (2024-05-01)

Allele-Specific PCR for PIK3CA Mutation Detection Using Phosphoryl Guanidine Modified Primers
by: Alexey S. Chubarov, et al.
Published: (2023-01-01)

Determination of the frequency and distribution of APC, PIK3CA, and SMAD4 gene mutations in Ugandan patients with colorectal cancer
by: Richard Wismayer, et al.
Published: (2024-09-01)

LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome
by: Diana E. Ramirez-Ardila, et al.
Published: (2016-10-01)

Promising Response with PI3K Inhibitor for a Patient with Heavily Pretreated PIK3CA Mutation Head-and-Neck Cancer
by: Ming-Jing Lee, et al.
Published: (2023-04-01)

Predicting breast cancer prognosis using PR and PIK3CA biomarkers: a comparative analysis of diagnostic groups
by: Yuting Feng, et al.
Published: (2025-01-01)

The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer
by: Maria Letizia Cataldo, et al.
Published: (2023-07-01)

Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example
by: Shutao Zheng, et al.
Published: (2024-04-01)

Characterizing multi‐PIK3CA mutations across cancer types: Toward precision oncology
by: Kohei Nakamura, et al.
Published: (2024-07-01)

Views on the Current Diagnosis and Treatment of PIK3CA-Related Overgrowth Spectrum
by: SUN Liying, et al.
Published: (2023-10-01)

PIK3CA-related overgrowth spectrum: animal model and drug discovery
by: Venot, Quitterie, et al.
Published: (2021-07-01)

Targeting p85β nuclear translocation for the tumors with PIK3CA helical domain mutations
by: Baoyu He, et al.
Published: (2022-11-01)